Leerink Swann Reaffirms Outperform Rating for Audentes Therapeutics (BOLD)

Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “outperform” rating reissued by equities researchers at Leerink Swann in a report released on Wednesday, The Fly reports. They presently have a $48.00 price target on the biotechnology company’s stock, up from their previous price target of $37.00. Leerink Swann’s target price would suggest a potential upside of 25.92% from the stock’s current price.

Several other brokerages have also commented on BOLD. BidaskClub raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 23rd. ValuEngine raised shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Zacks Investment Research lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective on shares of Audentes Therapeutics in a research report on Friday, January 11th. Finally, Mizuho reissued a “buy” rating and issued a $45.00 price objective on shares of Audentes Therapeutics in a research report on Friday, February 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $38.76.

Shares of BOLD traded down $2.88 on Wednesday, hitting $38.12. 3,811 shares of the stock traded hands, compared to its average volume of 477,942. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -11.23 and a beta of 1.96. Audentes Therapeutics has a 1 year low of $17.95 and a 1 year high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.08. During the same quarter in the previous year, the company posted ($0.82) EPS. As a group, equities research analysts expect that Audentes Therapeutics will post -3.83 earnings per share for the current fiscal year.

In other news, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $30.00, for a total value of $630,000.00. Following the completion of the transaction, the chief executive officer now directly owns 135,700 shares in the company, valued at $4,071,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis G. Lange sold 20,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $36.00, for a total transaction of $720,000.00. Following the completion of the transaction, the director now owns 306,099 shares of the company’s stock, valued at $11,019,564. The disclosure for this sale can be found here. Insiders sold 51,000 shares of company stock valued at $1,650,600 in the last three months. Company insiders own 6.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of BOLD. Partner Fund Management L.P. increased its holdings in shares of Audentes Therapeutics by 94.4% in the 4th quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock worth $64,413,000 after acquiring an additional 1,467,120 shares during the period. BlackRock Inc. increased its holdings in shares of Audentes Therapeutics by 15.8% in the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock worth $63,418,000 after acquiring an additional 406,605 shares during the period. Great Point Partners LLC acquired a new stake in shares of Audentes Therapeutics in the 4th quarter worth about $35,346,000. Vanguard Group Inc increased its holdings in shares of Audentes Therapeutics by 1.9% in the 3rd quarter. Vanguard Group Inc now owns 1,342,931 shares of the biotechnology company’s stock worth $53,166,000 after acquiring an additional 24,585 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Audentes Therapeutics by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,342,931 shares of the biotechnology company’s stock worth $53,166,000 after acquiring an additional 24,585 shares during the period.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

The Fly

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.